Trial Details

RECRUITING
Basic Information
Clinical ID c896
Identifier NCT05186623
Trial Title Prediction Model for Response to Biologics and Small Molecular Agent for UC
Trial URL Visit Original Page
Study Information
Study Results

NO

Conditions Ulcerative Colitis
Interventions DRUG: Vedolizumab, Ustekinumab, or Tofacitinib
Participant Information
Sponsor Asan Medical Center
City Seoul
Country/Region Korea, Republic of
Enrollment Criteria
Sex Requirement ALL
Age Requirement ADULT, OLDER_ADULT
Study Design
Study Type OBSERVATIONAL
Phase -
Time Information
Start Date 2022-02-05
Primary Completion Date 2026-12-31
Completion Date 2026-12-31